Pneumococcal vaccine

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Streptococcus pneumoniae (pneumococcus) is an important pathogen with high morbidity and mortality worldwide. Pneumococcal vaccine is an important measure to reduce the pneumococcal disease burden. Currently, two pneumococcal vaccines are available in adults, including 23-valent pneumococcal polysaccharide vaccine (PPV23) and 13-valent pneumococcal protein-conjugate vaccine (PCV13). PCV13 consists of capsular polysaccharides derived from the 13 most common types that cause invasive diseases (serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19F, 19A, and 23F). PPV23 covers 10 additional serotypes compared to PCV13, but it does not include serotype 6A. Even though limited in the number of serotypes, PCV13 has several important advantages over PPV23: T-cell dependent superior immunogenicity, booster effect, absence of hypo-responsiveness and protective effect on pneumonia. Although PPV23 is effective to prevent 50% to 80% of invasive pneumococcal diseases, it may be ineffective for high-risk immunocompetent and immunocompromised patients. In adults, the choice of pneumococcal vaccine should be based on the severity of underlying medical conditions and local serotype distribution. Serotype distribution is quite variable temporally and geographically. Continuous sero-surveillance is essential for the establishment of optimal vaccination strategy.

Original languageEnglish
Pages (from-to)780-788
Number of pages9
JournalJournal of the Korean Medical Association
Volume57
Issue number9
DOIs
Publication statusPublished - 2014 Jan 1

Fingerprint

Pneumococcal Vaccines
Streptococcus pneumoniae
Conjugate Vaccines
Immunocompromised Host
Polysaccharides
Serogroup
Pneumonia
Vaccination
Morbidity
T-Lymphocytes
Mortality
Proteins

Keywords

  • Pneumococcal infections
  • Pneumococcal vaccines
  • Streptococcus pneumoniae

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Pneumococcal vaccine. / Song, Joon-Young; Cheong, Hee-Jin.

In: Journal of the Korean Medical Association, Vol. 57, No. 9, 01.01.2014, p. 780-788.

Research output: Contribution to journalArticle

@article{1071ac71b07f4ede8bf5c98d0b29aa08,
title = "Pneumococcal vaccine",
abstract = "Streptococcus pneumoniae (pneumococcus) is an important pathogen with high morbidity and mortality worldwide. Pneumococcal vaccine is an important measure to reduce the pneumococcal disease burden. Currently, two pneumococcal vaccines are available in adults, including 23-valent pneumococcal polysaccharide vaccine (PPV23) and 13-valent pneumococcal protein-conjugate vaccine (PCV13). PCV13 consists of capsular polysaccharides derived from the 13 most common types that cause invasive diseases (serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19F, 19A, and 23F). PPV23 covers 10 additional serotypes compared to PCV13, but it does not include serotype 6A. Even though limited in the number of serotypes, PCV13 has several important advantages over PPV23: T-cell dependent superior immunogenicity, booster effect, absence of hypo-responsiveness and protective effect on pneumonia. Although PPV23 is effective to prevent 50{\%} to 80{\%} of invasive pneumococcal diseases, it may be ineffective for high-risk immunocompetent and immunocompromised patients. In adults, the choice of pneumococcal vaccine should be based on the severity of underlying medical conditions and local serotype distribution. Serotype distribution is quite variable temporally and geographically. Continuous sero-surveillance is essential for the establishment of optimal vaccination strategy.",
keywords = "Pneumococcal infections, Pneumococcal vaccines, Streptococcus pneumoniae",
author = "Joon-Young Song and Hee-Jin Cheong",
year = "2014",
month = "1",
day = "1",
doi = "10.5124/jkma.2014.57.9.780",
language = "English",
volume = "57",
pages = "780--788",
journal = "Journal of the Korean Medical Association",
issn = "1975-8456",
publisher = "Korean Medical Association",
number = "9",

}

TY - JOUR

T1 - Pneumococcal vaccine

AU - Song, Joon-Young

AU - Cheong, Hee-Jin

PY - 2014/1/1

Y1 - 2014/1/1

N2 - Streptococcus pneumoniae (pneumococcus) is an important pathogen with high morbidity and mortality worldwide. Pneumococcal vaccine is an important measure to reduce the pneumococcal disease burden. Currently, two pneumococcal vaccines are available in adults, including 23-valent pneumococcal polysaccharide vaccine (PPV23) and 13-valent pneumococcal protein-conjugate vaccine (PCV13). PCV13 consists of capsular polysaccharides derived from the 13 most common types that cause invasive diseases (serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19F, 19A, and 23F). PPV23 covers 10 additional serotypes compared to PCV13, but it does not include serotype 6A. Even though limited in the number of serotypes, PCV13 has several important advantages over PPV23: T-cell dependent superior immunogenicity, booster effect, absence of hypo-responsiveness and protective effect on pneumonia. Although PPV23 is effective to prevent 50% to 80% of invasive pneumococcal diseases, it may be ineffective for high-risk immunocompetent and immunocompromised patients. In adults, the choice of pneumococcal vaccine should be based on the severity of underlying medical conditions and local serotype distribution. Serotype distribution is quite variable temporally and geographically. Continuous sero-surveillance is essential for the establishment of optimal vaccination strategy.

AB - Streptococcus pneumoniae (pneumococcus) is an important pathogen with high morbidity and mortality worldwide. Pneumococcal vaccine is an important measure to reduce the pneumococcal disease burden. Currently, two pneumococcal vaccines are available in adults, including 23-valent pneumococcal polysaccharide vaccine (PPV23) and 13-valent pneumococcal protein-conjugate vaccine (PCV13). PCV13 consists of capsular polysaccharides derived from the 13 most common types that cause invasive diseases (serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19F, 19A, and 23F). PPV23 covers 10 additional serotypes compared to PCV13, but it does not include serotype 6A. Even though limited in the number of serotypes, PCV13 has several important advantages over PPV23: T-cell dependent superior immunogenicity, booster effect, absence of hypo-responsiveness and protective effect on pneumonia. Although PPV23 is effective to prevent 50% to 80% of invasive pneumococcal diseases, it may be ineffective for high-risk immunocompetent and immunocompromised patients. In adults, the choice of pneumococcal vaccine should be based on the severity of underlying medical conditions and local serotype distribution. Serotype distribution is quite variable temporally and geographically. Continuous sero-surveillance is essential for the establishment of optimal vaccination strategy.

KW - Pneumococcal infections

KW - Pneumococcal vaccines

KW - Streptococcus pneumoniae

UR - http://www.scopus.com/inward/record.url?scp=84907392949&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84907392949&partnerID=8YFLogxK

U2 - 10.5124/jkma.2014.57.9.780

DO - 10.5124/jkma.2014.57.9.780

M3 - Article

AN - SCOPUS:84907392949

VL - 57

SP - 780

EP - 788

JO - Journal of the Korean Medical Association

JF - Journal of the Korean Medical Association

SN - 1975-8456

IS - 9

ER -